Replies to post #15009 on Innovus Pharmaceuticals Inc. (fka INNV)

[gi197845]

I did not expect all 220,000 fluticare units to have been fully sold, but many of them, with hopefully talk of a reorder, which was not the case.

I wonder why INNV had such a good Q1 and why you think Q2 will be much lower? I like a realistic view of course, but I would hope that peak allergy season in Q2 would make Q2 sales much like Q1.

Dr.Damaj stated last year that INNV could be profitable at 10-12million, but now it looks like even at 18million, profitability is being questioned?

I would hope, that INNV has at least, at least a 18million dollar 2018, but I would not be surprised if it came in at 15million or below.

Let's get the SG&A down and the sales up.

[jtaylor68]

Q2 will almost certainly be higher than Q1 revs. It's a wholly unfounded assumption that revs will drop to the level you mentioned. It simply makes no sense whatsoever.

Enlighten us, what makes you keep your shares if you allegedly see Innovus missing guidance and profitability again? You only see negatives and still you remain invested. Does that make sense in your head?